These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32733937)

  • 1. Recurrent Neoantigens in Colorectal Cancer as Potential Immunotherapy Targets.
    Chen C; Liu S; Qu R; Li B
    Biomed Res Int; 2020; 2020():2861240. PubMed ID: 32733937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
    Chen C; Zhou Q; Wu R; Li B; Chen Q; Zhang X; Shi C
    Biomed Res Int; 2019; 2019():2183510. PubMed ID: 31781598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer.
    Yao P; Gao M; Hu W; Wang J; Wang Y; Wang Q; Ji J
    Pharmacol Res; 2024 Jun; 204():107209. PubMed ID: 38740147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
    Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
    J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A method of screening highly common neoantigens with immunogenicity in colorectal cancer based on public somatic mutation library].
    Qin LL; Li YJ; Liang ZR; Dai L; Li WH; Chen C; Huang YL; Zhang L; Liu SM; Qiu S; Ge YP; Peng WT; Lin XX; Zhang XQ; Dong X; Li B
    Yi Chuan; 2020 Jun; 42(6):599-612. PubMed ID: 32694118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
    Zheng Y; Fu Y; Wang PP; Ding ZY
    Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
    Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
    Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving neoantigen profiles in colorectal cancers with DNA repair defects.
    Rospo G; Lorenzato A; Amirouchene-Angelozzi N; Magrì A; Cancelliere C; Corti G; Negrino C; Amodio V; Montone M; Bartolini A; Barault L; Novara L; Isella C; Medico E; Bertotti A; Trusolino L; Germano G; Di Nicolantonio F; Bardelli A
    Genome Med; 2019 Jun; 11(1):42. PubMed ID: 31253177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
    Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
    Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer.
    Zhou J; Zhao W; Wu J; Lu J; Ding Y; Wu S; Wang H; Ding D; Mo F; Zhou Z; Teng L; Chen S
    Biomed Res Int; 2019; 2019():8103142. PubMed ID: 31312661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction.
    Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B
    Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
    Zhou S; Liu S; Zhao L; Sun HX
    Front Oncol; 2022; 12():786438. PubMed ID: 35387130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations.
    Iiizumi S; Ohtake J; Murakami N; Kouro T; Kawahara M; Isoda F; Hamana H; Kishi H; Nakamura N; Sasada T
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30813491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.
    Wang C; Ding Y; Liu Y; Zhang Q; Xu S; Xia L; Duan H; Wang S; Ji P; Huang W; Zhao G; Cao Z; Shen H; Wang Y
    Front Immunol; 2020; 11():576603. PubMed ID: 33329543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalised neoantigen-based therapy in colorectal cancer.
    Zhu YJ; Li X; Chen TT; Wang JX; Zhou YX; Mu XL; Du Y; Wang JL; Tang J; Liu JY
    Clin Transl Med; 2023 Nov; 13(11):e1461. PubMed ID: 37921274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer vaccines: Tumor-associated antigens
    Wagner S; Mullins CS; Linnebacher M
    World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.